Diclofenac sodium topical solution with dimethyl sulfoxide, a viable alternative to oral nonsteroidal anti-inflammatories in osteoarthritis: Review of current evidence

Journal of Multidisciplinary Healthcare

Volumn 4, Issue , 2011, Pages 223-231

  Fuller, Philip ^a   Roth, Sanford ^b  

^a MEDTRONIC INC   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Diclofenac; Nonsteroidal anti inflammatory drugs; Osteoarthritis; Topical analgesic

Indexed keywords

EID: 84866500859     PISSN: None     EISSN: 11782390     Source Type: Journal    
DOI: 10.2147/JMDH.S23209     Document Type: Article

References (46)

1. Lawrence RC, Felson DT, Helmick CG, et al. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008; 58(1):26–35.
2. Bitton R. The economic burden of osteoarthritis. Am J Manag Care. 2009;15(Suppl 8):S230–S235.
3. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 2000;43(9):1905–1915.
4. Jordan KM, Arden NK, Doherty M, et al. Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145–1155.
5. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137–162.
6. Tannenbaum H, Bombardier C, Davis P, Russell AS. Third Canadian Consensus Conference Group. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol. 2006;33(1):140–157.
7. Chou R, Helfand M, Peterson K, Dana T, Roberts C. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis. Comparative Effectiveness Review No. 4. Rockville, MD: agency for Healthcare Research and Quality; September 2006. Available from: http://www. effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed May 5, 2010.
8. National Collaborating Centre for Chronic Conditions. Osteoarthritis: National Clinical Guideline for Care and Management in Adults. London, UK: Royal College of Physicians; 2008. Available from: http://www.nice. org.uk/nicemedia/pdf/cg059fullguideline.pdf. Accessed May 5, 2010.
9. Roth SH. Nonsteroidal antiinflammatory drug gastropathy: we started it, why don’t we stop it? J Rheum. 2005;32(7):1189–1191.
10. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634–1642.
11. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;331(7528):1310–1316.
12. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials. BMJ. 2006;332(7553):1302–1308.
13. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, Laupacis A. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ. 2004;328(7453):1415–1416.
14. Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord. 2007;8:73.
15. Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal antiinflammatory drugs. Expert Opin Drug Saf. 2009;8(6):669–681.
16. Moore RA, Derry S, McQuay HJ. Topical agents in the treatment of rheumatic pain. Rheum Dis Clin North Am. 2008;34(2):415–432.
17. American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatric Soc. 2009;57(8): 1331–1346.
18. Voltaren Gel (diclofenac sodium topical gel) 1% Prescribing information. Chadds Ford, PA: Endo Pharmaceuticals Inc; 2009.
19. Pennsaid (diclofenac sodium topical solution) 1.5% w/w Prescribing information. Hazelwood, MO: Mallinckrodt Inc; 2010.
20. Hewitt PG, Poblete N, Wester RC, Maibach HI, Shainhouse JZ. In vitro cutaneous disposition of a topical diclofenac lotion in human skin: effect of a multi-dose regimen. Pharm Res. 1998;15(7):988–992.
21. Wiechers JW. The barrier function of the skin in relation to percutaneous absorption of drugs. Pharm Weekbl Sci. 1989;11(6):185–198.
22. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56(5):603–618.
23. Bookman AA, Williams KS, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ. 2004;171(4):333–338.
24. Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med. 2004;164(18):2017–2023.
25. Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord. 2005;6:44.
26. Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143(3):238–245.
27. ®) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004;31(10):2002–2012.
28. Altman RD, Hochberg M, Murphy WAJ, Wolfe E, Lequesne M. Atlas of individual radiographic features in osteoarthritis. Osteoarthritis Cartilage. 1995;(3Suppl A):3–70.
29. Bellamy N, Kirwan J, Boers M, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol. 1997;24(4):799–802.
30. Altman R, Brandt K, Hochberg M, et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage. 1996;4(4):217–243.
31. Group for the Respect of Ethics and Excellence in Science (GREES): Osteoarthritis section. Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis. 1996;55(8): 552–557.
32. Bellamy N, Carette S, Ford PM, et al. Osteoarthritis antirheumatic drug trials. III. Setting the delta for clinical trials – results of a consensus development (Delphi) exercise. J Rheumatol. 1992;19(3):451–457.
33. Hui X, Hewitt PG, Poblete N, Maibach HI, Shainhouse JZ, Wester RC. In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers. Pharm Res. 1998;15(10):1589–1595.
34. Kienzler JL, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol. 2010;50(1):50–61.
35. Rochon PA, Binns MA, Litner JA, et al. Are randomized control trial outcomes influenced by the inclusion of a placebo group? A systematic review of nonsteroidal antiinflammatory drug trials for arthritis treatment. J Clin Epidemiol. 1999;52(2):113–122.
36. Shainhouse JZ, Grierson LM, Naseer Z. A long-term, open-label study to confirm the safety of topical diclofenac solution containing dimethyl sulfoxide in the treatment of the osteoarthritic knee. Am J Ther. 2010; 17(6):566–576.
37. Rubin LF. Toxicologic update of dimethyl sulfoxide. Ann N Y Acad Sci. 1983;411:6–10.
38. Brobyn RD. The human toxicology of dimethyl sulfoxide. Ann N Y Acad Sci. 1975;243:497–506.
39. Garcia CA. Ocular toxicology of dimethyl sulfoxide and effects on retinitis pigmentosa. Ann N Y Acad Sci. 1983;411:48–51.
40. Shirley HH, Lundergan MK, Williams HJ, Spruance SL. Lack of ocular changes with dimethyl sulfoxide therapy of scleroderma. Pharmacotherapy. 1989;9(3):165–168.
41. Taylor HR, Muñoz B. The incidence and progression of lens opacities. Aust N Z J Ophthalmol. 1991;19(4):353–356.
42. Italian-American Cataract Study Group. Incidence and progression of cortical, nuclear, and posterior subcapsular cataracts. Am J Ophthalmol. 1994;118(5):623–631.
43. Leske MC, Chylack LT Jr, He Q, et al. Incidence and progression of cortical and posterior subcapsular opacities: the Longitudinal Study of Cataract. The LSC Group. Ophthalmology. 1997;104(12): 1987–1993.
44. Leske MC, Chylack LT Jr, Wu SY, et al. Incidence and progression of nuclear opacities in the Longitudinal Study of Cataract. Ophthalmology. 1996;103(5):705–712.
45. Klein BE, Klein R, Lee KE. Incidence of age-related cataract: the Beaver Dam Eye Study. Arch Ophthalmol. 1998;116(2):219–225.
46. US Food and Drug Administration. Public Health Advisory – FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Available from: http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ucm150314.htm. Accessed August 11, 2010.